Activation of Nrf2 Signaling Augments Vesicular Stomatitis Virus Oncolysis via Autophagy-Driven Suppression of Antiviral Immunity

Molecular Therapy

Volumn 25, Issue 8, 2017, Pages 1900-1916

  Olagnier, David ^a,b,h   Lababidi, Rassin R ^a,b   Hadj, Samar Bel ^a   Sze, Alexandre ^a,b   Liu, Yiliu ^a,b   Naidu, Sharadha Dayalan ^c   Ferrari, Matteo ^g   Jiang, Yuan ^a,b   Chiang, Cindy ^d   Beljanski, Vladimir ^e   Goulet, Marie Line ^a   Knatko, Elena V ^c   Dinkova Kostova, Albena T ^c,f   Hiscott, John ^g   Lin, Rongtuan ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

^d UNIVERSITY OF CHICAGO   (United States)

^e NOVA SOUTHEASTERN UNIVERSITY   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Pasteur Institute   (Italy)

^h AARHUS UNIVERSITY   (Denmark)

Author keywords

autophagy; cancer; innate antiviral response; interferon; Nrf2; oncolysis; VSV

Indexed keywords

INTERFERON; ONCOLYTIC VIRUS; SULFORAPHANE; TRANSCRIPTION FACTOR NRF2; ANTINEOPLASTIC AGENT; ANTIOXIDANT; ISOTHIOCYANIC ACID DERIVATIVE; MATRIX PROTEIN; SULFORAFAN;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CANCER CELL; CONTROLLED STUDY; CYTOKINE RESPONSE; CYTOTOXICITY; DRUG EFFECT; GENE ACTIVATION; GENE CONTROL; HUMAN; HUMAN CELL; IMMUNITY; ISOGRAFT; LUNG CANCER; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TREATMENT OUTCOME; TUMOR XENOGRAFT; VESICULOVIRUS; VIRUS REPLICATION; XENOPHAGY; ANIMAL; AUTOPHAGY; CELL LINE; DISEASE MODEL; DRUG EFFECTS; GENE DELETION; GENETICS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; INNATE IMMUNITY; KNOCKOUT MOUSE; METABOLISM; MORTALITY; MULTIMODALITY CANCER THERAPY; NEOPLASM; PATHOLOGY; PHYSIOLOGY; VESICULAR STOMATITIS; VESICULAR STOMATITIS INDIANA VIRUS; VIROLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; AUTOPHAGY; CELL LINE; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY; IMMUNITY, INNATE; ISOTHIOCYANATES; MICE; MICE, KNOCKOUT; NEOPLASMS; NF-E2-RELATED FACTOR 2; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; SEQUENCE DELETION; SIGNAL TRANSDUCTION; VESICULAR STOMATITIS; VESICULAR STOMATITIS INDIANA VIRUS; VIRAL MATRIX PROTEINS; VIRUS REPLICATION;

EID: 85020103515     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1016/j.ymthe.2017.04.022     Document Type: Article

References (71)

1. Ilkow, C.S., Swift, S.L., Bell, J.C., Diallo, J.S., From scourge to cure: tumour-selective viral pathogenesis as a new strategy against cancer. PLoS Pathog., 10, 2014, e1003836.
2. Breitbach, C.J., Lichty, B.D., Bell, J.C., Oncolytic viruses: therapeutics with an identity crisis. EBioMedicine 9 (2016), 31–36.
3. Swift, S.L., Stojdl, D.F., Big data offers novel insights for oncolytic virus immunotherapy. Viruses, 8, 2016, 45.
4. Lichty, B.D., Breitbach, C.J., Stojdl, D.F., Bell, J.C., Going viral with cancer immunotherapy. Nat. Rev. Cancer 14 (2014), 559–567.
5. Rehman, H., Silk, A.W., Kane, M.P., Kaufman, H.L., Into the clinic: talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy. J. Immunother. Cancer, 4, 2016, 53.
6. Russell, S.J., Peng, K.W., Bell, J.C., Oncolytic virotherapy. Nat. Biotechnol. 30 (2012), 658–670.
7. Altomonte, J., Wu, L., Chen, L., Meseck, M., Ebert, O., García-Sastre, A., Fallon, J., Woo, S.L., Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo. Mol. Ther. 16 (2008), 146–153.
8. Arulanandam, R., Batenchuk, C., Varette, O., Zakaria, C., Garcia, V., Forbes, N.E., Davis, C., Krishnan, R., Karmacharya, R., Cox, J., et al. Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing. Nat. Commun., 6, 2015, 6410.
9. Ben Yebdri, F., Van Grevenynghe, J., Tang, V.A., Goulet, M.L., Wu, J.H., Stojdl, D.F., Hiscott, J., Lin, R., Triptolide-mediated inhibition of interferon signaling enhances vesicular stomatitis virus-based oncolysis. Mol. Ther. 21 (2013), 2043–2053.
10. Nguyên, T.L., Abdelbary, H., Arguello, M., Breitbach, C., Leveille, S., Diallo, J.S., Yasmeen, A., Bismar, T.A., Kirn, D., Falls, T., et al. Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc. Natl. Acad. Sci. USA 105 (2008), 14981–14986.
11. Ottolino-Perry, K., Diallo, J.S., Lichty, B.D., Bell, J.C., McCart, J.A., Intelligent design: combination therapy with oncolytic viruses. Mol. Ther. 18 (2010), 251–263.
12. Shulak, L., Beljanski, V., Chiang, C., Dutta, S.M., Van Grevenynghe, J., Belgnaoui, S.M., Nguyên, T.L., Di Lenardo, T., Semmes, O.J., Lin, R., Hiscott, J., Histone deacetylase inhibitors potentiate vesicular stomatitis virus oncolysis in prostate cancer cells by modulating NF-κB-dependent autophagy. J. Virol. 88 (2014), 2927–2940.
13. Dobson, C.C., Naing, T., Beug, S.T., Faye, M.D., Chabot, J., St-Jean, M., Walker, D.E., LaCasse, E.C., Stojdl, D.F., Korneluk, R.G., Holcik, M., Oncolytic virus synergizes with Smac mimetic compounds to induce rhabdomyosarcoma cell death in a syngeneic murine model. Oncotarget 8 (2017), 3495–3508.
14. Marchini, A., Scott, E.M., Rommelaere, J., Overcoming barriers in oncolytic virotherapy with HDAC inhibitors and immune checkpoint blockade. Viruses, 8, 2016, 9.
15. Breitbach, C.J., Reid, T., Burke, J., Bell, J.C., Kirn, D.H., Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval. Cytokine Growth Factor Rev. 21 (2010), 85–89.
16. Rowan, K., Oncolytic viruses move forward in clinical trials. J. Natl. Cancer Inst. 102 (2010), 590–595.
17. Stojdl, D.F., Lichty, B., Knowles, S., Marius, R., Atkins, H., Sonenberg, N., Bell, J.C., Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 6 (2000), 821–825.
18. Stojdl, D.F., Lichty, B.D., tenOever, B.R., Paterson, J.M., Power, A.T., Knowles, S., Marius, R., Reynard, J., Poliquin, L., Atkins, H., et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4 (2003), 263–275.
19. Samuel, S., Tumilasci, V.F., Oliere, S., Nguyên, T.L., Shamy, A., Bell, J., Hiscott, J., VSV oncolysis in combination with the BCL-2 inhibitor obatoclax overcomes apoptosis resistance in chronic lymphocytic leukemia. Mol. Ther. 18 (2010), 2094–2103.
20. Nguyen, T., Nioi, P., Pickett, C.B., The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J. Biol. Chem. 284 (2009), 13291–13295.
21. Baird, L., Llères, D., Swift, S., Dinkova-Kostova, A.T., Regulatory flexibility in the Nrf2-mediated stress response is conferred by conformational cycling of the Keap1-Nrf2 protein complex. Proc. Natl. Acad. Sci. USA 110 (2013), 15259–15264.
22. Jaramillo, M.C., Zhang, D.D., The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev. 27 (2013), 2179–2191.
23. Greaney, A.J., Maier, N.K., Leppla, S.H., Moayeri, M., Sulforaphane inhibits multiple inflammasomes through an Nrf2-independent mechanism. J. Leukoc. Biol. 99 (2016), 189–199.
24. Qi, T., Xu, F., Yan, X., Li, S., Li, H., Sulforaphane exerts anti-inflammatory effects against lipopolysaccharide-induced acute lung injury in mice through the Nrf2/ARE pathway. Int. J. Mol. Med. 37 (2016), 182–188.
25. Traka, M., Gasper, A.V., Melchini, A., Bacon, J.R., Needs, P.W., Frost, V., Chantry, A., Jones, A.M., Ortori, C.A., Barrett, D.A., et al. Broccoli consumption interacts with GSTM1 to perturb oncogenic signalling pathways in the prostate. PLoS ONE, 3, 2008, e2568.
26. Alumkal, J.J., Slottke, R., Schwartzman, J., Cherala, G., Munar, M., Graff, J.N., Beer, T.M., Ryan, C.W., Koop, D.R., Gibbs, A., et al. A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer. Invest. New Drugs 33 (2015), 480–489.
27. Cipolla, B.G., Mandron, E., Lefort, J.M., Coadou, Y., Della Negra, E., Corbel, L., Le Scodan, R., Azzouzi, A.R., Mottet, N., Effect of sulforaphane in men with biochemical recurrence after radical prostatectomy. Cancer Prev. Res. (Phila.) 8 (2015), 712–719.
28. van Die, M.D., Bone, K.M., Emery, J., Williams, S.G., Pirotta, M.V., Paller, C.J., Phytotherapeutic interventions in the management of biochemically recurrent prostate cancer: a systematic review of randomised trials. BJU Int. 117:Suppl 4 (2016), 17–34.
29. Furfaro, A.L., Traverso, N., Domenicotti, C., Piras, S., Moretta, L., Marinari, U.M., Pronzato, M.A., Nitti, M., The Nrf2/HO-1 axis in cancer cell growth and chemoresistance. Oxid. Med. Cell. Longev., 2016, 2016, 1958174.
30. Jeong, Y., Hoang, N.T., Lovejoy, A., Stehr, H., Newman, A.M., Gentles, A.J., Kong, W., Truong, D., Martin, S., Chaudhuri, A., et al. Role of KEAP1/NRF2 and TP53 mutations in lung squamous cell carcinoma development and radiation resistance. Cancer Discov. 7 (2017), 86–101.
31. Singh, A., Misra, V., Thimmulappa, R.K., Lee, H., Ames, S., Hoque, M.O., Herman, J.G., Baylin, S.B., Sidransky, D., Gabrielson, E., et al. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med., 3, 2006, e420.
32. Lee, Y.J., Jeong, H.Y., Kim, Y.B., Lee, Y.J., Won, S.Y., Shim, J.H., Cho, M.K., Nam, H.S., Lee, S.H., Reactive oxygen species and PI3K/Akt signaling play key roles in the induction of Nrf2-driven heme oxygenase-1 expression in sulforaphane-treated human mesothelioma MSTO-211H cells. Food Chem. Toxicol. 50 (2012), 116–123.
33. Lee, Y.J., Lee, S.H., Sulforaphane induces antioxidative and antiproliferative responses by generating reactive oxygen species in human bronchial epithelial BEAS-2B cells. J. Korean Med. Sci. 26 (2011), 1474–1482.
34. Dinkova-Kostova, A.T., Holtzclaw, W.D., Cole, R.N., Itoh, K., Wakabayashi, N., Katoh, Y., Yamamoto, M., Talalay, P., Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc. Natl. Acad. Sci. USA 99 (2002), 11908–11913.
35. Biswas, C., Shah, N., Muthu, M., La, P., Fernando, A.P., Sengupta, S., Yang, G., Dennery, P.A., Nuclear heme oxygenase-1 (HO-1) modulates subcellular distribution and activation of Nrf2, impacting metabolic and anti-oxidant defenses. J. Biol. Chem. 289 (2014), 26882–26894.
36. Herman-Antosiewicz, A., Johnson, D.E., Singh, S.V., Sulforaphane causes autophagy to inhibit release of cytochrome C and apoptosis in human prostate cancer cells. Cancer Res. 66 (2006), 5828–5835.
37. Jounai, N., Takeshita, F., Kobiyama, K., Sawano, A., Miyawaki, A., Xin, K.Q., Ishii, K.J., Kawai, T., Akira, S., Suzuki, K., Okuda, K., The Atg5 Atg12 conjugate associates with innate antiviral immune responses. Proc. Natl. Acad. Sci. USA 104 (2007), 14050–14055.
38. Pajares, M., Jiménez-Moreno, N., García-Yagüe, A.J., Escoll, M., de Ceballos, M.L., Van Leuven, F., Rábano, A., Yamamoto, M., Rojo, A.I., Cuadrado, A., Transcription factor NFE2L2/NRF2 is a regulator of macroautophagy genes. Autophagy 12 (2016), 1902–1916.
39. Hiscott, J., Triggering the innate antiviral response through IRF-3 activation. J. Biol. Chem. 282 (2007), 15325–15329.
40. Zhang, Y., Talalay, P., Cho, C.G., Posner, G.H., A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc. Natl. Acad. Sci. USA 89 (1992), 2399–2403.
41. Fahey, J.W., Zhang, Y., Talalay, P., Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. Proc. Natl. Acad. Sci. USA 94 (1997), 10367–10372.
42. Lenzi, M., Fimognari, C., Hrelia, P., Sulforaphane as a promising molecule for fighting cancer. Cancer Treat. Res. 159 (2014), 207–223.
43. Dinkova-Kostova, A.T., Fahey, J.W., Kostov, R.V., Kensler, T.W., KEAP1 and done? Targeting the NRF2 pathway with sulforaphane. Trends Food Sci. Technol., 2017, 10.1016/j.tifs.2017.02.002 Published online February 16, 2017.
44. Singh, S.V., Srivastava, S.K., Choi, S., Lew, K.L., Antosiewicz, J., Xiao, D., Zeng, Y., Watkins, S.C., Johnson, C.S., Trump, D.L., et al. Sulforaphane-induced cell death in human prostate cancer cells is initiated by reactive oxygen species. J. Biol. Chem. 280 (2005), 19911–19924.
45. Hu, C., Eggler, A.L., Mesecar, A.D., van Breemen, R.B., Modification of keap1 cysteine residues by sulforaphane. Chem. Res. Toxicol. 24 (2011), 515–521.
46. Zhang, D.D., Hannink, M., Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol. Cell. Biol. 23 (2003), 8137–8151.
47. McMahon, M., Lamont, D.J., Beattie, K.A., Hayes, J.D., Keap1 perceives stress via three sensors for the endogenous signaling molecules nitric oxide, zinc, and alkenals. Proc. Natl. Acad. Sci. USA 107 (2010), 18838–18843.
48. Alexander, A., Cai, S.L., Kim, J., Nanez, A., Sahin, M., MacLean, K.H., Inoki, K., Guan, K.L., Shen, J., Person, M.D., et al. ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. Proc. Natl. Acad. Sci. USA 107 (2010), 4153–4158.
49. Otterbein, L.E., Hedblom, A., Harris, C., Csizmadia, E., Gallo, D., Wegiel, B., Heme oxygenase-1 and carbon monoxide modulate DNA repair through ataxia-telangiectasia mutated (ATM) protein. Proc. Natl. Acad. Sci. USA 108 (2011), 14491–14496.
50. Alain, T., Lun, X., Martineau, Y., Sean, P., Pulendran, B., Petroulakis, E., Zemp, F.J., Lemay, C.G., Roy, D., Bell, J.C., et al. Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. Proc. Natl. Acad. Sci. USA 107 (2010), 1576–1581.
51. Yang, G., Lee, H.E., Lee, J.Y., A pharmacological inhibitor of NLRP3 inflammasome prevents non-alcoholic fatty liver disease in a mouse model induced by high fat diet. Sci. Rep., 6, 2016, 24399.
52. Liu, Z., Ravindranathan, R., Kalinski, P., Guo, Z.S., Bartlett, D.L., Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nat. Commun., 8, 2017, 14754.
53. Simpson, G.R., Relph, K., Harrington, K., Melcher, A., Pandha, H., Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances. Oncolytic Virother. 5 (2016), 1–13.
54. Rajani, K.R., Vile, R.G., Harnessing the power of onco-immunotherapy with checkpoint inhibitors. Viruses 7 (2015), 5889–5901.
55. Bridle, B.W., Clouthier, D., Zhang, L., Pol, J., Chen, L., Lichty, B.D., Bramson, J.L., Wan, Y., Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8(+) T-cell responses to anticancer vaccines. OncoImmunology, 2, 2013, e26013.
56. Bridle, B.W., Chen, L., Lemay, C.G., Diallo, J.S., Pol, J., Nguyen, A., Capretta, A., He, R., Bramson, J.L., Bell, J.C., et al. HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy. Mol. Ther. 21 (2013), 887–894.
57. Lemay, C.G., Keller, B.A., Edge, R.E., Abei, M., Bell, J.C., Oncolytic viruses: the best is yet to come. Curr. Cancer Drug Targets, 2017, 10.2174/1568009617666170206111609 Published online February 6, 2017.
58. Kallifatidis, G., Labsch, S., Rausch, V., Mattern, J., Gladkich, J., Moldenhauer, G., Büchler, M.W., Salnikov, A.V., Herr, I., Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate. Mol. Ther. 19 (2011), 188–195.
59. Erzinger, M.M., Bovet, C., Hecht, K.M., Senger, S., Winiker, P., Sobotzki, N., Cristea, S., Beerenwinkel, N., Shay, J.W., Marra, G., et al. Sulforaphane preconditioning sensitizes human colon cancer cells towards the bioreductive anticancer prodrug PR-104A. PLoS ONE, 11, 2016, e0150219.
60. Higgins, L.G., Hayes, J.D., The cap'n'collar transcription factor Nrf2 mediates both intrinsic resistance to environmental stressors and an adaptive response elicited by chemopreventive agents that determines susceptibility to electrophilic xenobiotics. Chem. Biol. Interact. 192 (2011), 37–45.
61. Wakabayashi, N., Itoh, K., Wakabayashi, J., Motohashi, H., Noda, S., Takahashi, S., Imakado, S., Kotsuji, T., Otsuka, F., Roop, D.R., et al. Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat. Genet. 35 (2003), 238–245.
62. Kovac, S., Angelova, P.R., Holmström, K.M., Zhang, Y., Dinkova-Kostova, A.T., Abramov, A.Y., Nrf2 regulates ROS production by mitochondria and NADPH oxidase. Biochim. Biophys. Acta 1850 (2015), 794–801.
63. Kuma, A., Hatano, M., Matsui, M., Yamamoto, A., Nakaya, H., Yoshimori, T., Ohsumi, Y., Tokuhisa, T., Mizushima, N., The role of autophagy during the early neonatal starvation period. Nature 432 (2004), 1032–1036.
64. Olagnier, D., Scholte, F.E., Chiang, C., Albulescu, I.C., Nichols, C., He, Z., Lin, R., Snijder, E.J., van Hemert, M.J., Hiscott, J., Inhibition of dengue and chikungunya virus infections by RIG-I-mediated type I interferon-independent stimulation of the innate antiviral response. J. Virol. 88 (2014), 4180–4194.
65. Chiang, C., Beljanski, V., Yin, K., Olagnier, D., Ben Yebdri, F., Steel, C., Goulet, M.L., DeFilippis, V.R., Streblow, D.N., Haddad, E.K., et al. Sequence-specific modifications enhance the broad-spectrum antiviral response activated by RIG-I agonists. J. Virol. 89 (2015), 8011–8025.
66. Olagnier, D., Peri, S., Steel, C., van Montfoort, N., Chiang, C., Beljanski, V., Slifker, M., He, Z., Nichols, C.N., Lin, R., et al. Cellular oxidative stress response controls the antiviral and apoptotic programs in dengue virus-infected dendritic cells. PLoS Pathog., 10, 2014, e1004566.
67. Belgnaoui, S.M., Paz, S., Samuel, S., Goulet, M.L., Sun, Q., Kikkert, M., Iwai, K., Dikic, I., Hiscott, J., Lin, R., Linear ubiquitination of NEMO negatively regulates the interferon antiviral response through disruption of the MAVS-TRAF3 complex. Cell Host Microbe 12 (2012), 211–222.
68. Zhao, T., Yang, L., Sun, Q., Arguello, M., Ballard, D.W., Hiscott, J., Lin, R., The NEMO adaptor bridges the nuclear factor-kappaB and interferon regulatory factor signaling pathways. Nat. Immunol. 8 (2007), 592–600.
69. Ivanov, A.V., Smirnova, O.A., Ivanova, O.N., Masalova, O.V., Kochetkov, S.N., Isaguliants, M.G., Hepatitis C virus proteins activate NRF2/ARE pathway by distinct ROS-dependent and independent mechanisms in HUH7 cells. PLoS ONE, 6, 2011, e24957.
70. Massrieh, W., Derjuga, A., Blank, V., Induction of endogenous Nrf2/small maf heterodimers by arsenic-mediated stress in placental choriocarcinoma cells. Antioxid. Redox Signal. 8 (2006), 53–59.
71. Song, W., Su, H., Song, S., Paudel, H.K., Schipper, H.M., Over-expression of heme oxygenase-1 promotes oxidative mitochondrial damage in rat astroglia. J. Cell. Physiol. 206 (2006), 655–663.